We scan new podcasts and send you the top 5 insights daily.
Tom cites EV303 and EV304 as showing similar pathological complete response rates after three versus four neoadjuvant EV cycles. That undercuts the clinical assumption that more neoadjuvant EV necessarily adds benefit, though the transcript gives no direct detail on those trials' designs or patient populations.
As neoadjuvant enfortumab vedotin plus pembrolizumab (EVP) achieves high pathologic complete response rates in MIBC, a critical question emerges: is adjuvant EVP necessary for everyone? Continuing treatment in patients who are already cancer-free post-surgery may offer no extra benefit while increasing toxicity.
Tom noted post-surgery ctDNA positivity fell to 5% on EV+Pembro versus 15% on chemotherapy, and the chemo arm also declined. He suspects surgery accounts for only part of the drop, with delayed immune clearance from EV+Pembro contributing; the durability of response evolves over months. So the surgical effect is not the whole story.
Rob points out all three chemo-IO trials raised pathological complete response by roughly 8-10%, yet only Niagara improved survival. He says path CR is not clinically meaningful by itself and has never been proven as a surrogate for event-free or overall survival. So similar activity signals cannot explain divergent outcomes.
An expert speculates that the durable responses and plateauing four-year survival curve from the EV302 trial indicate a potential cure rate of 30% in metastatic bladder cancer, a dramatic improvement over historical outcomes of 5-10%.
Tom points out that all patients received a year of adjuvant therapy in the experimental arms, but only about 25% of the ITT population completed all nine EV cycles, and little is known about who they were. The three-arm ad hoc analysis therefore cannot isolate the adjuvant phase's benefit or necessity.
Remarkable pathologic response rates from just 3-4 cycles of neoadjuvant EV-Pembro are creating divergent research questions. Future trials will explore whether some patients could benefit from more cycles (escalation) while high-responders might be able to skip cystectomy entirely (de-escalation).
Data from trials like CheckMate 816 shows that achieving a Pathologic Complete Response (PCR) after neoadjuvant chemo-immunotherapy is a powerful early surrogate endpoint. Patients with PCR demonstrate markedly improved overall and event-free survival.
While KEYNOTE-905 showed dramatic survival benefits with neoadjuvant plus adjuvant EV-pembrolizumab, its design makes it impossible to isolate the benefit of each phase. The high (57%) pathologic complete response after neoadjuvant therapy alone suggests many patients may be overtreated with adjuvant cycles, risking unnecessary long-term toxicity like neuropathy.
New bladder-sparing trials mandate nine cycles of EV-Pembro to replicate the conditions of successful surgical trials. This conservative approach ignores that patient response is front-loaded while toxicity is back-loaded, likely overtreating many patients to ensure comparable efficacy.
In clinical practice and clinical trial arms planned for nine perioperative cycles of EV-pembrolizumab, most patients fail to complete therapy due to adverse events. Consequently, real-world clinicians already administer de-escalated regimens resembling shorter three-cycle protocols out of necessity.